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Introduction
Th e term ‘idiopathic infl ammatory myopathy’ (IIM) 
usually refers to one of three related diseases: poly myo-
sitis (PM), dermatomyositis (DM), and inclusion body 
myositis (IBM). Each variation of the disease has defi ning 
characteristics (for example, the heliotrope rash of DM or 
the intramuscular rimmed vacuoles of IBM), but there 
are some common characteristics. In PM and DM, 
patients typically present clinically with diff use muscle 
weakness that is worse in proximal muscles than in distal 
muscles, whereas in IBM profound weakness may be 
present in both proximal and distal muscles. Histo logi-
cally, patients show muscle infl ammation, fi ber degenera-
tion, and overexpression of the MHC class I molecule 
[1-3]. Th is muscle pathology is not always uniform, and 
many patients display isolated patches of infl ammation 
and degeneration in otherwise healthy muscle tissue. In 
aff ected patients, signifi cant causes of morbidity and 
mortality include diffi  culty in performing daily activities, 
dysphagia, and respiratory failure [4,5]. Immunosuppres-
sive therapies such as prednisolone and methotrexate are 
common fi rst-line treatments, with cyclosporine and 
other powerful immunosuppressants as second-line agents 
[6-8]. Unfortunately, these current therapies have pro-
duced mixed results; for example, patients with DM are 
most likely to benefi t from glucocorticoid therapy (with a 
reduction in infl ammation, and improvement in muscle 
function), and most PM patients typically respond to 
immunosuppressive therapy [9-11]. On the other hand, 
patients with IBM (and a subset of PM patients) do not 
typically respond to either glucocorticoids or other 
immunosuppressant therapies [7]. Studies have shown 
that the therapeutic response to glucocorticoid treatment 
varies signifi cantly; furthermore, the degrees of infl am-
matory infi ltration and muscle function are dissociated, 
suggesting a role for other mechanisms in muscle dys-
func tion in these diseases [12,13]. Here we review some 
of the non-adaptive immune mechanisms that may be 
responsible for muscle weakness in the absence of overt 
infl ammation, and we provide evidence that skeletal 
muscle, but not infl ammation, is an active participant in 
the progression of muscle disease in these disorders.
Toll-like receptors on skeletal muscle
It is generally thought that skeletal muscle is merely a 
target of immune-mediated damage and that removal of 
immune cells from the milieu could result in preservation 
of skeletal muscle and improvement in skeletal muscle 
function. However, the fact that disease progression occurs 
in the absence of signifi cant infl ammation suggests that 
skeletal muscle itself contributes to the disease process. 
How the skeletal muscle senses signals from the injured 
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microenvironment clearly requires further study. Mam-
ma lian cells are able to rapidly and effi  ciently recognize 
not only foreign invaders such as microbes but also 
damage- or injury-associated self-proteins via germline-
encoded pattern recognition receptors. Th ese receptors 
recognize damage-associated molecular patterns (DAMPs), 
which are either derived from pathogens (pathogen-
associated molecular patterns, or PAMPs) or are self-
proteins (stress or danger-associated molecular patterns, 
or SAMPs) [14,15]. Recognition of damage-associated 
molecular patterns by Toll-like receptors (TLRs) initiates 
a signaling cascade, leading to the activation or inhibition 
of genes that control the infl ammatory response.
In chronic infl ammatory conditions such as myositis, 
some of the self-proteins released from damaged cells 
may act as SAMPs. TLRs are known to sense several of 
these endogenous ligands and activate infl ammatory 
signaling pathways [16]. It is important to consider this 
mechanism of infl am mation since some IIM patients can 
continue to experience muscle fi ber degeneration even 
after success ful suppression of autoreactive lymphocytes. 
In IIMs, several endogenous infl ammatory molecules 
(such as high mobility group box 1 (HMGB1), which is 
discussed in more detail later) have been proposed to 
play a role in disease pathogenesis [17,18]. Two separate 
investigations of patient biopsies have identifi ed TLR-3 
and TLR-7 (receptors for double-stranded RNA and GU-
rich single-stranded RNA, respectively) on the surface of 
regenerating muscle fi bers in patient biopsies [19,20]. 
TLRs have also been observed on skeletal muscle cells in 
other myopathies, where the activation of the innate 
immune pathway caused the skeletal muscle cells to 
secrete the infl ammatory cytokine IL-1β [21]. Interest-
ingly, the U1-snRNP molecule, which is capable of 
activat ing both TLR-3 and TLR-7, has been previously 
reported to be associated with several autoimmune 
rheumatoid diseases, and a small number of IIM patients 
develop anti-U1 autoantibodies [22,23]. Both HMGB1 
and U1-snRNP are nuclear proteins that are not found in 
the extracellular space in healthy tissue, thereby suggest-
ing that these endogenous TLR ligands may be released 
from infl amed or necrotic fi bers, which then induce 
infl ammation in neighboring fi bers.
Skeletal muscle cells secrete several cytokines and 
chemokines
Cytokines play a central role in the immune response by 
promoting the activation of antigen-specifi c and non-
specifi c eff ector mechanisms and tissue repair. Most 
discussions about cytokines revolve around their produc-
tion from lymphocytes, but it is important to consider 
cytokines that are produced from the skeletal muscle 
itself. Human skeletal muscle cells constitutively produce 
the cytokine IL-6, and its expression can be increased by 
stimulation with IL-1α, IL-1β, TNFα and IFNγ in a dose-
dependent manner [24,25]. IL-6 has a role in regulating 
metabolic rates in skeletal muscle, but it can also act as 
an infl ammatory molecule. Excessive secretion of IL-6 
has previously been linked to other autoimmune diseases 
(for example, rheumatoid arthritis) and is known to 
promote the development of potentially autoreactive 
T
H
-17 cells [26,27]. Th e pathogenic role of IL-6 in 
myositis has also been supported by IL-6 blockade in one 
mouse model of C-protein-induced myositis [28]. In IL-6 
knockout mice, both the incidence and the severity of 
myositis were reduced compared to C57BL/6 controls. It 
should also be noted that previous examinations of 
muscle biopsies from IIM patients have found fi bers that 
were positive for IL-1α, TNFα, and IL-1β staining, 
suggesting that lymphocytes may not be necessary to 
induce overexpression of IL-6 [29,30]. Furthermore, it 
has been suggested that a feedback loop linking IL-6 
production and TLR-3 stimulation exists in infl amed 
skeletal muscle, and may play a role in the pathogenesis 
of IIMs [19].
Apart from IL-6, recent investigations have confi rmed 
that IFNα plays a prominent role in the pathogenesis of 
IIMs [31-35]. Inquiries into the sources of some of the 
type I IFNs have indicated that dendritic cells and mast 
cells are the major producers of IFNα and IFNβ in DM 
patients. Th ese same cells are also known to be major 
producers of IL-1β [36,37]. IFNα is known to upregulate 
a number of antiviral target genes, such as MXA, IFIT2, 
and ISG15. Strong intramuscular staining for these IFNα 
targets has previously been observed in biopsies from 
DM and PM patients [34]. One such target, ISG15, is 
known to disrupt the normal ubiquitination process. 
During viral infections, ISG15 is substituted for ubiquitin 
and interferes with the maturation and function of viral 
proteins, such as the HIV Gag and Ebola VP40 proteins. 
Histological examination of muscle biopsies has revealed 
that ISG15 is absent from healthy muscle but is detect-
able in patients with PM, IBM, and DM [35]. Further 
experiments are still needed to establish the functional 
consequences of ISG15 expression in muscle cells. Th e 
clinical signifi cance of IFNα was underscored in a small 
study in which IIM patients failed to respond to 
infl iximab, and a worsening in symptoms was correlated 
with an increase in IFNα serum levels [31].
In addition to classical cytokines, non-traditional 
cytokines/chemokines also appear to play a signifi cant 
role in controlling the infl ammatory process. Two such 
proteins, histidyl tRNA synthetase (HisRS) and HMGB1, 
have been associated with myositis [18,38,39]. Th e 
infl am matory properties of the HMGB1 protein have 
previously been demonstrated in other infl ammatory 
diseases [40-42]. Th is non-histone nuclear protein acts as 
a potent infl ammatory molecule when released from 
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necrotic cells. HMGB1-mediated infl ammation is signaled 
through either TLR-4 or receptor for advanced glycation 
endproducts (RAGE) [43]. Examination of human muscle 
biopsies has revealed that cytoplasmic HMGB1 expres-
sion is widespread in PM and DM patients but absent 
from healthy controls. Furthermore, when isolated primary 
muscles fi bers are exposed to extracellular HMGB1 in 
vitro, the fi bers begin expressing MHC class I antigens on 
their surface and demonstrate an accelerated, dose-
dependent effl  ux of calcium ions [17], suggesting a role 
for HMGB1 in the perpetuation of infl ammation and 
muscle fi ber degeneration even in the absence of 
infi ltrating lymphocytes.
Role of MHC class I upregulation on skeletal muscle 
fi bers
MHC class I proteins are essential for immune surveil-
lance. Th ey are expressed on nearly all cells, with few 
exceptions (for example, mature neurons, oligo dendro-
cytes, pancreatic islet cells, and skeletal muscle fi bers). In 
these few cases, constitutive expression is either low or 
absent. As mentioned previously, one of the histological 
hallmarks of skeletal muscle in IIM is the widespread and 
constitutive presence of MHC class I protein [44-47]. 
Even though the immunological roles of these proteins 
(for example, antigen presentation) are well-studied, their 
non-immunological roles are not well defi ned. It is 
worthwhile to mention that other autoimmune diseases 
(for example, type I diabetes or multiple sclerosis) can be 
initiated by forced expression of the MHC class I in the 
few cell types (that is, pancreatic islet or oligodendrocyte 
cells) where it is normally absent [48,49]. It is not clear 
why MHC class I expression is restricted in these cell 
types, but one possible explanation can be found in 
recent research into the formation and maintenance of 
the neuromuscular junction (NMJ). Recent studies of 
neurons in the central nervous system have indicated 
that MHC class I expression is dynamic (as is that of its 
secondary receptors, CD3z and PirB) and is involved in 
communication across the synaptic junction and the 
maintenance of synaptic plasticity [50,51]. Th ese studies 
have indicated that classical MHC class I proteins are 
expressed in motor neurons, with predominant expres-
sion occurring at the presynaptic end of the NMJ. In 
another recent study, it was reported that a knockout of 
the MHC class I gene resulted in abnormally high 
densities of NMJs during development, and abnormal 
formation of NMJs after denervation and re-innervation 
[52]. Together, these reports suggest that MHC class I 
acts as a signaling molecule to promote pruning NMJs 
during development and potentially to force the 
remodeling of established NMJs. Th is newly discovered 
role for MHC class I may explain why its expression is so 
tightly controlled by the cells surrounding the NMJ 
(neurons, oligodendrocytes, and muscle fi bers). Under 
this model, the constitutive expression of MHC class I 
from the muscle may have a disruptive eff ect on the 
structure and/or function of the NMJ, though this 
hypothesis has not yet been tested.
The endoplasmic reticulum stress response pathway
Endoplasmic reticulum (ER) stress is a known cause of 
pathology in certain conditions, including viral infections 
and neurodegenerative disorders, and there is emerging 
evidence that ER stress within the muscle cells 
contributes to pathology in IIMs [53]. Th e ER is known as 
the site of protein synthesis, folding, post-translational 
modifi cation, lipid biosynthesis, and intracellular calcium 
storage within the cell. Since muscle contractions are 
signaled through calcium release, the regulation of intra-
cellular calcium concentrations is of paramount impor-
tance in muscle cells. Within muscle cells, the ER is a 
specially modifi ed organelle that is also known as the 
sarcoplasmic reticulum. Excessive changes in the load of 
proteins, composition of lipids, or calcium concentration 
within the ER can trigger multiple stress response path-
ways acting through ATF4 (activating transcription 
factor 4), ATF6 (activating transcription factor 6), and 
PERK (protein kinase RNA-like endoplasmic reticulum 
kinase). If the ER stress cannot be resolved, then the cell 
will initiate an apoptotic response via the expression of 
DDIT3 (DNA-damage-inducible transcript; also called 
CHOP) and activation of caspase 4 (or caspase-11 and 
caspase-12 in mice) [54-56]. Interestingly, there is some 
evidence to suggest that mature skeletal muscle, like 
pancreatic islet cells, may tax the sarcoplasmic reticulum 
to near its limits, even under conditions of normal 
protein synthesis [57].
We and others have suggested that, in myositis, over-
expression of the MHC class I molecule in skeletal 
muscle can induce ER stress. Th is hypothesis is based 
upon observations made in the transgenic mouse model 
of myositis [45,46,58] and in human patients with IIMs 
[47,59,60]. As described previously, skeletal muscle cells 
do not express detectable levels of MHC class I molecules 
under normal conditions, although transient expression 
can be observed following injury or viral infections. In 
the mouse model of myositis, the forced expression of 
MHC class I molecules is suffi  cient to precipitate the 
onset of myositis in mice. Histological and biochemical 
examinations of the mouse muscle tissue revealed ER 
stress in muscle fi bers, as evidenced by the upregulation 
of multiple ER chaperone proteins (for example, Grp78, 
Grp94, calnexin, calreticulin) and activation of the NF-κB 
pathway. Very similar changes were found in patients in 
whom muscle cells that were positive for MHC class I 
were also found to show increased expression of Grp78, 
Grp94, and calreticulin [47,61-63]. It should also be 
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noted that lymphocytic infi ltration was not correlated 
with staining for ER stress markers [47].
Several laboratories have examined the potential role of 
ER stress and ER stress-associated degradation in the 
accumulation of misfolded proteins in IBM patients. 
Histological analysis of patients with IBM has shown 
scattered inclusion bodies (thought to be protein 
aggregates) that are not seen in PM or DM. Th e appear-
ance of inclusion bodies can be hypothesized to be 
indicative of defective protein folding or defective degra-
da tion of misfolded proteins, although the available 
evidence seems to favor defective degradation. Examina-
tion of patients with IBM has revealed that the mRNA 
and protein expression of amyloid-B protein and BACE1 
(β-site amyloid-β precursor protein (AβPP)-cleaving 
enzyme 1) are increased in IBM muscle. However, it 
should be noted that the potential pathogenic role of β-
amyloid in IBM is a controversial topic [64,65]. In a 
separate investigation, patients with IBM were found to 
exhibit an increased expression of autophagosomes, a 
common ER stress response. Furthermore, the proteases 
cathepsin B and cathepsin D in patients with IBM 
showed diminished protease activity when compared to 
those in controls. Th ese data indicate that increased ER 
stress and protein aggregation may be the result of 
impaired protein degradation in IIMs [66].
Metabolic disturbances
Another potential mechanistic explanation for the 
persistent muscle weakness seen in IIMs comes from the 
observation that there is an apparent disturbance in 
patients’ metabolism and ATP production. Muscle fi bers 
are generally composed of type  I (slow-twitch) and 
type  II (fast-twitch) fi bers. Muscles composed of slow 
fi bers depend on oxidative phosphorylation and are 
responsible for long-term, low-force muscle activity. 
Conversely, muscles composed of fast-twitch fi bers often 
depend on glycolysis in order to carry out rapid, 
strenuous movements. However, in the case of IIM 
patients, there are indications that the fast-twitch fi bers 
are more prone to degenerate, and that these patients’ 
ability to produce ATP in the skeletal muscle may be 
impaired. Mass spectrometry analysis of myositis 
biopsies has shown a signifi cant loss of type II (fast-
twitch)-specifi c proteins (for example, myosin heavy 
chain  1 (MYH1), troponin  T3 (TNNT3), and actinin  3 
(ACTN3)) and a modest increase in type I (slow-twitch) 
muscle proteins (for example, myosin heavy chain  7 
(MYH7), troponin T1 (TNNTL1), and actinin 2 (ACNT2)) 
[64]. Similarly, IIM patients have shown a modest 
decrease in enzymes required for glycolysis in the muscle 
(for example, glycogen debranching enzyme (AGL), 
muscle phosphofructokinase (PFKM), fructose-1,6-bis-
phos phatase isozyme  2 (FBP2), and phosphoglycerate 
mutase  2 (PGAM)), with the most signifi cant decreases 
being found in patients with IBM [64].
In recent decades, the results of multiple studies have 
indicated that the loss of another type II-specifi c muscle 
enzyme, AMPD1, is potentially responsible for distur-
bances in ATP metabolism and muscle weakness [67,68]. 
Th ese fi ndings have been corroborated by magnetic 
resonance spectroscopy in patients with juvenile-onset 
DM; in that study, the stable isotope 31P was used to 
compare the levels of ATP, ADP, AMP, and phospho-
creatine in the quadriceps of DM patients and healthy 
controls. Th e DM patients were found to have roughly 
4.03  ±  0.26  mmoles/kg of total ATP, compared to 
6.26  ±  0.23  mmoles/kg in the controls. Th e concentra-
tions of ADP, AMP, and phosphocreatine were similarly 
decreased in the DM patients [69]. Interestingly, there is 
some evidence that chronic ER stress can alter the 
metabolism of muscle fi bers: activation of the unfolded 
protein response pathway in skeletal muscle has been 
reported to occur during exercise, with repeated 
activation of this pathway being linked to a gradual shift 
in muscle metabolism to adapt to exercise training. In 
addition, the transcriptional coactivator PGC-1α (per oxi-
some proliferator-activated receptor gamma coactivator 
1-alpha) has been found to interact with ATF6; prior 
investigations have linked PGC-1α to a role in promoting 
type I muscle fi ber genes, and ATF6 has been shown to 
be activated by ER stress. It is interesting to note that 
mice defi cient in ATF6 have an impaired ability to 
recover from exercise, while mice lacking PGC-1α ex-
peri ence exercise intolerance that can be partially reversed 
by inhibitors of CHOP [70]. Taken together, these results 
suggest that ER stress has impor tant consequences for 
metabolic homeostasis and force generation in skeletal 
muscle cells.
Role of hypoxia
Histological analysis of muscle from some IIM patients 
has shown that these patients have fewer capillaries per 
unit area in their skeletal muscle than do healthy patients 
[71,72]. Th is observation has led investigators to propose 
that the resulting lower oxygen levels are responsible for 
the muscle weakness seen in myositis patients. Gene 
profi ling of patient biopsies has revealed that both pro-
moters of angiogenesis (for example, hypoxia inducible 
factor (HIF)-1α, CD146, and fi bronectin) and inhibitors 
of angiogenesis (for example, CXCL10, transforming 
growth factor-β, and angiopoietin 2) are expressed simul-
taneously, indicating that capillaries are being actively 
remodeled in patients with myositis [73]. Th e transcrip-
tion factor HIF-1α is especially noteworthy because it is a 
direct sensor of hypoxia and helps to maintain oxygen 
homeostasis. A recent publication has corroborated these 
expression profi ling data by demonstrating that HIF-1 
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proteins accumulate in IIM patients [71,74]. Th is accu-
mu lation is possible only under low-oxygen conditions, 
indicating that the skeletal muscle of all IIM patients are 
very likely subjected to hypoxic conditions. Th is hypoxia 
hypothesis is supported by the reported benefi ts of 
physical exercise in myositis patients, suggesting a role 
for vascular endothelial cell dysfunction and hypoxia in 
the pathogenesis of IIMs [72,75].
Conclusion
Th e evidence to support a role for non-immune mecha-
nisms in the pathogenesis of IIMs is growing. Th ese data 
place the myofi ber at the center of disease pathobiology, 
with an initial insult to the myofi bers (whether viral, 
damage, or a genetic predisposition) leading to myofi ber 
TLR signaling, which in and of itself can induce weakness 
via type 1 IFN pathways by interfering with energy 
production and mitochondrial respiration. Infi ltrating 
leukocytes augment and exacerbate this signaling. Th e 
relationship between all of these pathologic mechanisms 
is shown in Figure  1, with a special emphasis on their 
convergence on the production of infl ammatory cyto-
kines. Th ese data also explain why immune suppression 
is variable in terms of its effi  cacy in restoring muscle 
strength, because the innate dysfunction of myofi bers 
remains despite the achievement of successful immune 
suppression.
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